COVID targets in the crosshairs: Achieving unparalleled quality and speed

Bringing new drugs to the market is an expensive and slow process that is commonly associated with long cycle times, and high costs and failure rates. 


In the drug screening pipeline and in pharmaceutical research in general, operational vulnerabilities such as low reproducibility and inefficient processes typically delay a drug´s path to approval.


In this talk, Daniel Thomas, Head of Discovery Biology at Arctoris, describes the acceleration of onboarding and validation of three critical assays targeted on SARS-CoV-2 drug discovery. These three case studies focus on key target functions such as viral processing, infectivity and transmission.